Patents Assigned to Trustees of the University of Pennsylvania
  • Patent number: 11041012
    Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: June 22, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Nathalie Scholler, Katarzyna Urbanska, Daniel J. Powell
  • Patent number: 11041171
    Abstract: Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: June 22, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Patent number: 11040324
    Abstract: Polyelectrolyte microcapsules, and methods for making and using the polyelectrolyte microcapsules, are described. A method of making polyelectrolyte microcapsules includes forming an “interfacial complexation in emulsion” (ICE), wherein a polyelectrolyte “shell” is formed by complexing two different polyelectrolytes together at an interface between two immiscible fluids. Both hydrophilic and hydrophobic materials can be incorporated into the cores and shells of the polyelectrolyte microcapsules.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: June 22, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Daeyeon Lee, Junsang Doh, Miju Kim, Martin F. Haase, Gang Duan
  • Patent number: 11034749
    Abstract: The present invention includes methods and compositions for treating cancer, whether a solid tumor or a hematologic malignancy. By expressing a chimeric antigen receptor in a monocyte, macrophage or dendritic cell, the modified cell is recruited to the tumor microenvironment where it acts as a potent immune effector by infiltrating the tumor and killing the target cells. One aspect includes a modified cell and pharmaceutical compositions comprising the modified cell for adoptive cell therapy and treating a disease or condition associated with immunosuppression.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: June 15, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Saar Gill, Michael Klichinsky, Carl H. June
  • Patent number: 11034994
    Abstract: The present invention is directed to a phospholipid-based NIR molecular beacon, having a phospholipid moiety; with an NIR fluorophore moiety covalently linked to a phospholipid glycerol backbone and a quencher moiety covalently linked to the phospholipid glycerol backbone. Additionally, provided herein is methods of analyzing a sample for the presence of a phospholipase and methods of identifying the activity of a phospholipase in vivo utilizing phospholipid-based NIR molecular beacon.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: June 15, 2021
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Edward J. Delikatny, Anatoliy V. Popov, Gang Zheng, Theresa Mawn
  • Patent number: 11034976
    Abstract: Adeno-associated virus rh.10 sequences, vectors containing same, and methods of use are provided.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: June 15, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Patent number: 11034977
    Abstract: Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: June 15, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Patent number: 11033567
    Abstract: This invention is directed to compositions for promoting wound healing and regeneration and methods of use thereof. In one aspect, methods for promoting wound healing in a subject are provided, the methods comprising: administering a therapeutically effective amount of a DNA methyl transferase inhibitors (DNMT) to the subject. In another aspect, methods for reducing scarring during healing of a skin wound are provided, the methods comprising: administering a therapeutically effective amount of a DNMT inhibitor.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: June 15, 2021
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: George Cotsarelis, Jen-Chih Hsieh, Ying Zheng
  • Patent number: 11035866
    Abstract: The application relates to markers for seizures and epilepsy. Polypeptide expression panels or arrays are provided, comprising one or more probes capable of binding specific polypeptides in blood plasma or blood serum of a mammalian subject. Also provided are methods for detecting seizure, methods for predicting seizure, use of sICAM-5 in the treatment of seizure, methods for assessing the effectiveness of a treatment of seizure, and diagnostic kits.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: June 15, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John Robert Pollard, Peter B. Crino
  • Patent number: 11026945
    Abstract: Disclosed herein are methods of preventing and/or treating lung injury and/or lung inflammation in a subject comprising administering to the subject a therapeutically effective dose of a PERK pathway inhibitor. Pharmaceutical compositions for the prevention and/or treatment of lung injury and/or lung inflammation comprising PERK pathway inhibitors are also provided. Also disclosed are uses of a PERK inhibitor in the manufacture of a medicament for the prevention and/or treatment of a lung injury and/or inflammation.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: June 8, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Susan S. Margulies, Tamas Dolinay
  • Patent number: 11027009
    Abstract: Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: June 8, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Matthew Morrow
  • Patent number: 11027514
    Abstract: The presently disclosed subject matter relates to nanocardboard structures and methods of fabrication thereof. An exemplary nanocardboard structure includes at least two parallel planar films and webbing. The planar films can be separated from each other by a gap of from about 0.1 micrometers to about 1000 micrometers.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: June 8, 2021
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Igor Bargatin, Chen Lin, Samuel Nicaise
  • Patent number: 11026976
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: June 8, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Walter Granda, Lu Huang, Ming Lei, Na Li, Jimin Zhang, Carla Guimaraes, Saar Gill, Marco Ruella, Regina M. Young
  • Patent number: 11028143
    Abstract: The invention provides T cells comprising nucleic acid sequence encoding a chimeric antigen receptor and a nucleic acid sequence encoding an enhancer of T cell priming, compositions including the T cells, and methods of using the T cells to treat diseases associated with the expression of disease-associated antigens.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: June 8, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Devon J. Shedlock, Carl H. June, Xiaojun Liu
  • Patent number: 11027011
    Abstract: Disclosed herein is a vaccine comprising an antigen and one or more bimolecular adjuvant. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: June 8, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Karuppiah Muthumani
  • Patent number: 11028372
    Abstract: A two-step chromatography purification scheme is described which selectively captures and isolates the genome-containing rAAV vector particles from the clarified, concentrated supernatant of a rAAV production cell culture. The process utilizes an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at high pH to provide rAAV vector particles which are substantially free of rAAV intermediates.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: June 8, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Martin Lock, Mauricio Alvira
  • Patent number: 11028389
    Abstract: This invention provides a method for enhancing utrophin protein production in a cell by inhibiting an utrophin microRNA molecule. Moreover, the invention provides that methods for enhancing utrophin protein production in a muscle cell are used for treating a muscular dystrophy and/or other myopathies.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: June 8, 2021
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Tejvir S. Khurana, Steve Wilton
  • Patent number: 11028177
    Abstract: The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML) and B-cell acute lymphoid leukemia (B-ALL). The invention also relates to at least one chimeric antigen receptor (CAR) specific to CD123, vectors comprising the same, and recombinant T cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD123 binding domain. The invention also includes methods of bone marrow ablation for use in treatments necessitating bone marrow reconditioning or transplant.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: June 8, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Saar Gill, Carl H. June, Michael D. Kalos, Andreas Loew, John Scholler
  • Patent number: 11021502
    Abstract: Compositions and methods of capturing one or more nucleic acid molecules of a cell or subcellular compartment are described. In certain aspects, the compositions comprise a caged molecule comprising one or more photolinkers and an antisense oligonucleotide, which when uncaged hybridizes to a target nucleic acid molecule.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: June 1, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James Eberwine, Ivan J. Dmochowski, Sean B. Yeldell, Julianne C. Griepenburg, Teresa L. Rapp, Jennifer M. Singh, Jai-Yoon Sul, Jaehee Lee
  • Patent number: 11020456
    Abstract: The inventive subject matter relates to novel methods for modulating an immune response in an animal, which comprises administering to said animal an effective amount of an agent that increases IL-27R/WSX-1 activity. Further, the inventive subject matter relates to pharmaceutical compositions comprising an effective amount of an agent that increases IL-27R/WSX-1 activity.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: June 1, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Christopher A. Hunter, Alejandro Villarino